Beta-Lactam Probability of Target Attainment Success: Cefepime As a Case Study

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Mar 29

PMID 36978312

Authors

Daniel J Selig

Adrian T Kress

Robert J Nadeau

Jesse P DeLuca

Affiliations

Soon will be listed here.

Abstract

Introduction: Probability of target attainment (PTA) analysis using Monte Carlo simulations has become a mainstay of dose optimization. We highlight the technical and clinical factors that may affect PTA for beta-lactams.

Methods: We performed a mini review in adults to explore factors relating to cefepime PTA success and how researchers incorporate PTA into dosing decisions. In addition, we investigated, via simulations with a population pharmacokinetic (PK) model, factors that may affect cefepime PTA success.

Results: The mini review included 14 articles. PTA results were generally consistent, given the differences in patient populations. However, dosing recommendations were more varied and appeared to depend on the definition of pharmacodynamic (PD) target, definition of PTA success and specific clinical considerations. Only 3 of 14 articles performed formal toxicological analysis. Simulations demonstrated that the largest determinants of cefepime PTA were the choice of PD target, continuous vs. intermittent infusion and creatinine clearance. Assumptions for protein binding, steady state vs. first dose, and simulating different sampling schemes may impact PTA success under certain conditions. The choice of one or two compartments had a minimal effect on PTA.

Conclusions: PTA results may be similar with different assumptions and techniques. However, dose recommendation may differ significantly based on the selection of PD target, definition of PTA success and considerations specific to a patient population. Demographics and the PK parameters used to simulate time-concentration profiles should be derived from patient data applicable to the purpose of the PTA. There should be strong clinical rationale for dose selection. When possible, safety and toxicity should be considered in addition to PTA success.

Citing Articles

Animal Models in Regulatory Breakpoint Determination: Review of New Drug Applications of Approved Antibiotics from 2014-2022.

Selig D, Caridha D, Evans M, Kress A, Lanteri C, Ressner R J Pers Med. 2024; 14(1).

PMID: 38276233 PMC: 10820112. DOI: 10.3390/jpm14010111.

References

Lau C, Marriott D, Schultz H, Gould M, Andresen D, Wicha S . Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. Int J Antimicrob Agents. 2021; 58(6):106443. DOI: 10.1016/j.ijantimicag.2021.106443. View

Scharf C, Liebchen U, Paal M, Taubert M, Vogeser M, Irlbeck M . The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. J Intensive Care. 2020; 8(1):86. PMC: 7686672. DOI: 10.1186/s40560-020-00504-w. View

Liu J, Rhodes N, Roberts J, Pais G, Turner B, Kiel P . β-lactam dosing strategies: Think before you push. Int J Antimicrob Agents. 2020; 56(5):106151. DOI: 10.1016/j.ijantimicag.2020.106151. View

Barbhaiya R, Knupp C, Forgue S, Matzke G, Guay D, PITTMAN K . Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990; 48(3):268-76. DOI: 10.1038/clpt.1990.149. View

Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A . Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study. J Intensive Care. 2018; 6:61. PMC: 6134777. DOI: 10.1186/s40560-018-0330-8. View

Shorr A, Bruno C, Zhang Z, Jensen E, Gao W, Feng H . Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Crit Care. 2021; 25(1):354. PMC: 8487337. DOI: 10.1186/s13054-021-03773-5. View

Wang C, Bai Y, Li R, Shen C, Zhang J . Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China. Diagn Microbiol Infect Dis. 2020; 97(2):115039. DOI: 10.1016/j.diagmicrobio.2020.115039. View

Sember A, LoFaso M, Lewis S . An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy. J Crit Care. 2022; 69:154011. DOI: 10.1016/j.jcrc.2022.154011. View

Huang C, Shi Q, Zheng B, Ji J, Ying C, Yu X . Simulating moxalactam dosage for extended-spectrum β-lactamase-producing using blood antimicrobial surveillance network data. Infect Drug Resist. 2019; 12:1199-1208. PMC: 6522843. DOI: 10.2147/IDR.S193712. View

10.

Kidd J, Stein G, Nicolau D, Kuti J . Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. J Clin Pharmacol. 2019; 60(2):172-180. DOI: 10.1002/jcph.1510. View

11.

Povoa P, Moniz P, Goncalves Pereira J, Coelho L . Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. Microorganisms. 2021; 9(7). PMC: 8305961. DOI: 10.3390/microorganisms9071401. View

12.

Masich A, Heavner M, Gonzales J, Claeys K . Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients. Curr Infect Dis Rep. 2018; 20(5):9. DOI: 10.1007/s11908-018-0613-1. View

13.

Alzahrani A, Hakami A, AlAzmi A, Karim S, Ali A, Burzangi A . Augmented Renal Clearance and Hypoalbuminemia-Induced Low Vancomycin Trough Concentrations in Febrile Neutropenic Patients With Hematological Malignancies. Cureus. 2022; 14(9):e29568. PMC: 9595576. DOI: 10.7759/cureus.29568. View

14.

Hirai K, Ishii H, Shimoshikiryo T, Shimomura T, Tsuji D, Inoue K . Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin. Ther Drug Monit. 2016; 38(6):706-710. DOI: 10.1097/FTD.0000000000000346. View

15.

Das S, FitzGerald R, Ullah A, Bula M, Collins A, Mitsi E . Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrob Agents Chemother. 2020; 65(1). PMC: 7927813. DOI: 10.1128/AAC.01468-20. View

16.

Onufrak N, Forrest A, Gonzalez D . Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther. 2016; 38(9):1930-47. PMC: 5039113. DOI: 10.1016/j.clinthera.2016.06.015. View

17.

Por E, Akers K, Chung K, Livezey J, Selig D . Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System. J Clin Pharmacol. 2021; 61(9):1182-1194. PMC: 8453752. DOI: 10.1002/jcph.1865. View

18.

Roberts J, Paul S, Akova M, Bassetti M, De Waele J, Dimopoulos G . DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis. 2014; 58(8):1072-83. DOI: 10.1093/cid/ciu027. View

19.

Xu X, Yuan M, Zhu H, Yang Y, Wang H, Zhou H . Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity. Br J Clin Pharmacol. 2018; 84(7):1525-1534. PMC: 6005596. DOI: 10.1111/bcp.13577. View

20.

Kollef M, Shorr A, Bassetti M, Timsit J, Micek S, Michelson A . Timing of antibiotic therapy in the ICU. Crit Care. 2021; 25(1):360. PMC: 8518273. DOI: 10.1186/s13054-021-03787-z. View